rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
9
|
pubmed:dateCreated |
2007-8-24
|
pubmed:abstractText |
Chemoresistance often leads to loss of the last treatment option for cancer. 2-Methoxyestradiol (2-ME2) has been shown to inhibit tumor growth. The aim was to examine the efficacy of 2-ME2 on multidrug-resistant human cells from pancreatic and gastric cancer.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0815-9319
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1469-73
|
pubmed:meshHeading |
pubmed-meshheading:17645459-Antineoplastic Agents,
pubmed-meshheading:17645459-Apoptosis,
pubmed-meshheading:17645459-Cell Division,
pubmed-meshheading:17645459-Cell Line, Tumor,
pubmed-meshheading:17645459-Drug Resistance, Multiple,
pubmed-meshheading:17645459-Estradiol,
pubmed-meshheading:17645459-Humans,
pubmed-meshheading:17645459-P-Glycoprotein,
pubmed-meshheading:17645459-Pancreatic Neoplasms,
pubmed-meshheading:17645459-Phenotype,
pubmed-meshheading:17645459-Stomach Neoplasms
|
pubmed:year |
2007
|
pubmed:articleTitle |
Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes.
|
pubmed:affiliation |
Department of General, Visceral, and Transplantation Surgery, Charité Campus Virchow Klinikum, Berlin, Germany. guido.schumacher@charite.de
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|